title: Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece.
abstract: The in vitro activity of plazomicin was evaluated against 300 multidrug resistant (MDR) (carbapenemase and/or ESBL-producing) isolates from four hospitals in Athens, an area where carbapenemase-producing organisms are endemic. Most of the isolates were also resistant to the legacy aminoglycosides with the MIC₅₀/MIC₉₀ to tobramycin, amikacin and gentamicin being 32/>32, 32/>32 and 4/>8 μg/ml, respectively. ACHN-490 retained activity (MICs ≤ 4 μg/ml) against all isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. tested with MIC₅₀ and MIC₉₀ of 1 and 2 μg/ml, respectively, irrespective of their MDR phenotype and it represents a promising alternative for the treatment of the most problematic Gram-negative pathogens.
authors.affiliation: 4th Department of Internal Medicine, Molecular Biology Section, Athens University School of Medicine, Chaidari, Greece. egalani@med.uoa.gr
authors.forename: Irene
authors.initials: I
authors.lastname: Galani
authors.forename: Maria
authors.initials: M
authors.lastname: Souli
authors.forename: George L
authors.initials: GL
authors.lastname: Daikos
authors.forename: Zoi
authors.initials: Z
authors.lastname: Chrysouli
authors.forename: Garyphalia
authors.initials: G
authors.lastname: Poulakou
authors.forename: Mina
authors.initials: M
authors.lastname: Psichogiou
authors.forename: Theofano
authors.initials: T
authors.lastname: Panagea
authors.forename: Athina
authors.initials: A
authors.lastname: Argyropoulou
authors.forename: Ioanna
authors.initials: I
authors.lastname: Stefanou
authors.forename: George
authors.initials: G
authors.lastname: Plakias
authors.forename: Helen
authors.initials: H
authors.lastname: Giamarellou
authors.forename: George
authors.initials: G
authors.lastname: Petrikkos
mesh_terms: D000583:Amikacin / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D024901:Drug Resistance, Multiple, Bacterial; D004754:Enterobacter / Q000187:drug effects* / Q000302:isolation & purification / Q000378:metabolism; D004756:Enterobacteriaceae Infections / Q000382:microbiology; D004926:Escherichia coli / Q000187:drug effects* / Q000302:isolation & purification / Q000378:metabolism; D004927:Escherichia coli Infections / Q000382:microbiology; D005839:Gentamicins / Q000494:pharmacology; D006115:Greece; D006801:Humans; D007710:Klebsiella Infections / Q000382:microbiology; D007711:Klebsiella pneumoniae / Q000187:drug effects* / Q000302:isolation & purification / Q000378:metabolism; D008826:Microbial Sensitivity Tests; D012853:Sisomicin / Q000031:analogs & derivatives* / Q000494:pharmacology; D062606:Tertiary Care Centers; D014031:Tobramycin / Q000494:pharmacology
chemical_list: D000900:Anti-Bacterial Agents; D005839:Gentamicins; D000583:Amikacin; C550938:plazomicin; D014031:Tobramycin; D012853:Sisomicin